At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 172 enrolled
Drug / intervention
OTX-DED +2 moredrug
Likely dose
OTX-DED 0.2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Masked, Vehicle-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of OTX-DED (Dexamethasone Intracanalicular Ophthalmic Insert) for the Short-Term Treatment of Signs and Symptoms of Dry Eye Disease (DED)
In Brief
A Phase 2 clinical trial evaluating OTX-DED for Dry Eye. Completed, enrolled 172 participants across 15 sites.
Detailed Summary
To assess the efficacy and safety of OTX-DED for the short-term treatment of signs and symptoms of dry eye disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDry Eye
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartFeb 2021
Primary CompletionAug 2021
Study CompletionSep 2021
TodayJul 2026
First PostedFeb 10, 2021
Enrollment StartFeb 12, 2021
Primary CompletionAug 11, 2021
Study CompletionSep 22, 2021
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 5.4 years ago
Interventions
OTX-DEDdrug
0.2mg dexamethasone ophthalmic insert
OTX-DEDdrug
0.3mg dexamethasone ophthalmic insert
OTX-DEDdrug
Hydrogel vehicle ophthalmic insert